DJ Sartorius Stedim Biotech SA: Sartorius Stedim Biotech completes acquisition of Polyplus
Sartorius Stedim Biotech SA / Key word(s): Mergers & Acquisitions/Acquisition
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech completes acquisition of Polyplus
18-Jul-2023 / 13:15 CET/CEST
=----------------------------------------------------------------------------------------------------------------------
Aubagne, July 18, 2023
Sartorius Stedim Biotech completes acquisition of Polyplus
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has successfully closed
the acquisition of the French company Polyplus. The transaction was completed on July 18, 2023, after receiving the
required regulatory approvals.
Polyplus is a leading provider of innovative technologies for cell and gene therapies. Transfection reagents developed
and produced by Polyplus are key components in the manufacture of viral vectors. The company has been expanding its
focus beyond this field through acquisitions in adjacent technologies like plasmid design, and protein and plasmid
manufacturing, broadening its portfolio for gene therapies as well as gene-modified cell therapies.
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech
Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could
cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech
assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim
Biotech shall not assume any liability for the correctness of this release. The French press release is the legally
binding version.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications
safely, rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The
company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America
and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through
acquisitions of complementary technologies. In fiscal 2022, the company generated sales revenue of around 3.5 billion
euros. At the end of 2022, around 12,000 employees were working for customers around the globe.
Contact
Timo Lindemann
Corporate Communications
+49 (0)551 308 4724
timo.lindemann@sartorius.com
Follow Sartorius on Twitter and on LinkedIn.
=----------------------------------------------------------------------------------------------------------------------
Attachment
File: Press Release
=----------------------------------------------------------------------------------------------------------------------
Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
EQS News ID: 1682663
End of Announcement - EQS News Service
=------------------------------------------------------------------------------------
1682663 18-Jul-2023 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1682663&application_name=news
(END) Dow Jones Newswires
July 18, 2023 07:15 ET (11:15 GMT)
